Navigation Links
ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
Date:2/27/2008

rivate

practice, specializing in racing thoroughbred medicine and surgery. Dr.

Ferraro is internationally recognized for his knowledge and expertise

in equine athletic injuries and has over 35 years of experience in that

field. He also served as Clinical Professor of Surgery at UC Davis for

many years during and after his private practice career. His interest

in advanced therapies for equine injuries stems from years of practical

clinical challenges and the scientific research for more effective and

timely therapeutic interventions.

-- Dori L. Borjesson, DVM, MPVM, PhD, DACVP, is Associate Professor of

veterinary clinical pathology with the Department of Pathology,

Microbiology and Immunology, at the UC Davis School of Veterinary

Medicine. She is a diplomat of the American College of Veterinary

Pathology with specialty boards in clinical pathology. Dr. Borjesson's

research has focused on bacterial interactions with hematopoietic

progenitor cells and mechanisms of bacterial-induced alterations in

bone marrow proliferation and differentiation. She has extensive in

vivo and in vitro experience with murine and human cells including

cord-blood derived stem cells.

-- Larry Galuppo DVM, Dipl. ACVS, Associate Professor and Chief, Equine

Surgery, Department of Surgical & Radiological Sciences, UC Davis

School of Veterinary Medicine. Clinical expertise in equine orthopedic

surgery including tendon and ligament injuries, joint disease, with

special interest in traumatology and fracture repair. Research emphasis

on biomechanics of fracture generation, implant design and fracture

repair, with focus in novel healing methods for musculoskeletal

injuries utilizing regenerative medicine technology.

-- Sean D. Owens, DVM, MRCVS, DACVP, is Assistant Pr
'/>"/>

SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
2. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
3. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
6. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
7. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
8. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
9. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
10. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
11. AMDLs Chinese Subsidiary Wins Key Brand Excellence Award for Anti-Aging Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2009)TUSTIN, Calif., Dec. 3 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it will release its financial results for the second quarter of fiscal year 2010 on December 10, 2009 at 7
(Date:12/2/2009)MANILA, Philippines, Dec. 2 Spectrum Blue Steel is emerging as one of the fastest growing green energy companies on the planet. Through the efforts of True Green Energy Group and True Green Planet,s
(Date:12/2/2009)COPENHAGEN, Dec. 2 The world,s first concept demonstration tires made with BioIsoprene technology, a breakthrough alternative to replace a petrochemically produced ingredient in the manufacture of
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
Breaking Biology Technology:Peregrine Pharmaceuticals to Report Second Quarter FY 2010 Financial Results 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 2Spectrum Blue Steel partners with Famous Chemists for Procuring Profitable Applications from Garbage Using the Biosphere MKV and Electrostatic Precipitators 3The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3
(Date:12/4/2009)A major discovery is challenging accepted thinking about amyloids the fibrous protein deposits associated with diseases such as Alzheimer,s and Parkinson,s and may open up a potential new area for t
(Date:12/3/2009)In the 1980s, Harald zur Hausen and his co-workers discovered that specific types of human papillomavirus (HPV) cause cervical cancer. Scientists soon found out how these pathogens cause cells to dege
(Date:12/3/2009)The extinction of plant and animal species can be likened to emptying a museum of its collection, or dumping a cabinet full of potential medicines into the trash, or replacing every local cuisine with
Breaking Biology News(10 mins):New therapy targets for amyloid disease 2Papillomavirus silences innate immune response 2Species down, disease up 2Species down, disease up 3Species down, disease up 4Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 1Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 2Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 3Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 4Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 5Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 6Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 7Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 8Schering Plough Announces Phase II and III Data for Corifollitropin Alfa 12868 9Hormones May Affect Neurological Disease Risk 50513 1Hormones May Affect Neurological Disease Risk 50513 2Antibiotics May Boost Risk for Recurrent Ear Infection 50511 1Antibiotics May Boost Risk for Recurrent Ear Infection 50511 2
Mouse Anti-Mannose Receptor Monoclonal Antibody, Biotin Conjugated, Clone 15-Feb from Abcam
TE Buffer from Upstate
Mouse Anti-DcR1 Monoclonal Antibody, Biotin Conjugated, Clone DJR3 from Abcam
L-Selenomethionine from Calbiochem
Biology Products: